

Comparison of Low Fat and Low Carbohydrate Diets on Circulating Fatty Acid Composition and Markers of Inflammation

Cassandra E. Forsythe · Stephen D. Phinney · Maria Luz Fernandez · Erin E. Quann · Richard J. Wood · Doug M. Bibus · William J. Kraemer · Richard D. Feinman · Jeff S. Volek

Received: 5 July 2007 / Revised: 24 October 2007 / Accepted: 25 October 2007 / Published online: 29 November 2007
© AOCs 2007

Abstract Abnormal distribution of plasma fatty acids and increased inflammation are prominent features of metabolic syndrome. We tested whether these components of metabolic syndrome, like dyslipidemia and glycemia, are responsive to carbohydrate restriction. Overweight men and women with atherogenic dyslipidemia consumed ad libitum diets very low in carbohydrate (VLCKD) (1504 kcal:%CHO:fat:protein = 12:59:28) or low in fat (LFD) (1478 kcal:%CHO:fat:protein = 56:24:20) for 12 weeks. In comparison to the LFD, the VLCKD resulted in an increased proportion of serum total n-6 PUFA, mainly attributed to a marked increase in arachidonate (20:4n-6), while its biosynthetic metabolic intermediates were decreased. The n-6/n-3 and arachidonic/eicosapentaenoic acid ratio also increased sharply. Total saturated fatty acids

and 16:1n-7 were consistently decreased following the VLCKD. Both diets significantly decreased the concentration of several serum inflammatory markers, but there was an overall greater anti-inflammatory effect associated with the VLCKD, as evidenced by greater decreases in TNF- α , IL-6, IL-8, MCP-1, E-selectin, I-CAM, and PAI-1. Increased 20:4n-6 and the ratios of 20:4n-6/20:5n-3 and n-6/n-3 are commonly viewed as pro-inflammatory, but unexpectedly were consistently inversely associated with responses in inflammatory proteins. In summary, a very low carbohydrate diet resulted in profound alterations in fatty acid composition and reduced inflammation compared to a low fat diet.

Keywords Arachidonic acid · Palmitoleic acid · Ketogenic diet · Saturated fat · Metabolic syndrome

C. E. Forsythe · E. E. Quann · W. J. Kraemer · J. S. Volek (✉)
Department of Kinesiology, University of Connecticut,
2095 Hillside Road, Unit 1110, Storrs, CT 06269-1110, USA
e-mail: jeff.volek@uconn.edu

S. D. Phinney
School of Medicine, University of California, Davis, CA, USA

M. L. Fernandez · R. J. Wood · J. S. Volek
Department of Nutritional Science, University of Connecticut,
Storrs, CT, USA

D. M. Bibus
University of Minnesota and Lipid Technologies, LLC,
Austin, MN, USA

R. D. Feinman
Department of Biochemistry, SUNY Downstate Medical Center,
Brooklyn, NY, USA

Abbreviations

VLCKD	Very low carbohydrate ketogenic diet
LFD	Low fat diet
PL	Phospholipid
CE	Cholesteryl ester
CVD	Cardiovascular disease
RDA	Recommended daily allowance
BMI	Body mass index
IL	Interleukin
TNF- α	Tumor necrosis factor- α
VEGF	Vascular endothelial growth factor
IFN- γ	Interferon- γ
EGF	Epidermal growth factor
MCP-1	Monocyte chemoattractant protein-1
ICAM-1	Intracellular cellular adhesion molecule-1
VCAM-1	Vascular cellular adhesion molecule-1
NF- κ B	Nuclear factor-kappa B

CRP	C-reactive protein
TAG	Triglycerides

Introduction

Development of metabolic syndrome (insulin resistance syndrome) is associated with altered composition of circulating fatty acids characterized by higher saturated fatty acids (14:0, 16:0), higher palmitoleic acid (16:1n-7, the MUFA product derived from palmitic acid), higher dihomono- γ -linolenic acid (20:3n-6, the precursor of arachidonic acid), and lower levels of linoleic acid (18:2n-6) [1]. The effect of dietary fatty acid composition on circulating fatty acids [2] is not well understood. Two recent studies demonstrated that consumption of a diet higher in saturated fat resulted in lower circulating palmitic acid (16:0) in cholesteryl ester compared to a diet low in saturated fat [3, 4], a paradox likely explained by the level of carbohydrate [5] whose increase is known to be associated with de novo fatty acid synthesis [6] and decreased fatty acid oxidation. We have previously described a comparison between a very low carbohydrate diet (VLCKD) and a low fat diet (LFD) in subjects with features of metabolic syndrome. A notable finding was an inverse relationship between dietary and plasma saturated fatty acids (SFA). The VLCKD, with three-fold greater dietary SFA than the LFD, showed a consistently greater reduction in plasma SFA compared to the LFD [7].

Metabolic syndrome is generally defined by high fasting glucose, triglycerides (TG), blood pressure and waist circumference, and low HDL cholesterol. Resistance to the effects of insulin provides a metabolic basis for changes in these disparate physiologic markers as well an increasing number of associations that extend beyond the original description of the syndrome almost 20 years ago [8]. New features that appear to be associated with metabolic syndrome include disturbed circulating fatty acid composition, perturbed lipid metabolism and increased oxidative stress and inflammation [9]. Fatty acids contribute to overall inflammatory balance by several mechanisms. In macrophages, SFA activate toll-like receptor signaling leading to activation of nuclear factor-kappa B (NF- κ B) and expression of cyclooxygenase-2 [10, 11]. NF- κ B is a transcription factor that regulates over 100 genes, many with an established role in inflammatory responses and atherosclerosis, and may therefore represent a crucial link between fatty acids, metabolic syndrome and atherogenesis [12]. Arachidonic acid (20:4n-6) in membranes is commonly assumed to have a deleterious effect on overall inflammatory balance because of its enzymatic conversion to proinflammatory, proaggregative, and vasoconstrictive

eicosanoids (e.g., prostaglandin E₂, thromboxane A₂, leukotrienes B₄). Arachidonic acid is also capable of non-enzymatic conversion to other proinflammatory bioactive products (F₂-isoprostanes) via interaction with molecular oxygen. In contrast, eicosanoids derived from the 20-carbon n-3 PUFA, eicosapentaenoic acid (20:5n-3), have less potent inflammatory effects [13]. A recent report showed a marked increase in the plasma 20:4n-6/20:5n-3 ratio in subjects consuming a VLCKD, while CRP, a marker of constitutive inflammation, decreased slightly [14]. The relations between inflammatory markers and arachidonic acid metabolism are complex [15], and may be further modified by the level of dietary carbohydrate.

Carbohydrate restriction is generally effective at ameliorating those physiologic markers associated with metabolic syndrome: high fasting glucose and insulin, and particularly the atherogenic dyslipidemia characterized by high TG and low HDL [16–19]. The effects are presumed to be attributed to better regulation of plasma glucose and insulin levels and improvement in the hyperinsulinemia/insulin resistance that are fundamental features of metabolic syndrome. Here we evaluated circulating fatty acid composition in three lipid fractions as well as a large number of inflammatory markers and show that a VLCKD results in profound alterations in fatty acid composition and reduced inflammatory markers to a greater extent than a low fat diet.

Materials and Methods

Study Design and Subjects

Details of this investigation have been described previously [7]. In brief, 40 overweight men and women aged 18–55 year with a BMI >25 kg/m² participated in this 12 week randomized, controlled, dietary intervention trial comparing a VLCKD to a LFD. All participants were required to have atherogenic dyslipidemia defined by moderately elevated TG (150 to 500 mg/dl) and low HDL [<40 (men) or <50 (women) mg/dl]. The two dietary groups were balanced for gender, age and BMI. Exclusion criteria were any metabolic and endocrine disorders, use of glucose-lowering, lipid-lowering or vasoactive prescriptions or supplements, consumption of a VLCKD, or weight loss >5.0 kg in the past 3 months. Habitual physical activity was maintained throughout the study intervention and was documented daily. Blood was drawn at baseline and after 12 week of diet intervention in the morning after a 12 h overnight fast and a 24 h abstinence from alcohol and strenuous exercise. All procedures were approved by the Institutional Review Board of the University of Connecticut, and all participants provided written informed consent.

Dietary Intervention

Subjects received individual and personalized dietary counseling from Registered Dietitians during the dietary intervention. No explicit instructions were provided regarding caloric intake for either diet to allow expression of any non-cognitive aspects on food intake. Subjects received weekly follow-up counseling during which body mass was measured, compliance was assessed, and further dietetic education was provided. Dietary intake and compliance was assessed with detailed and weighed 7-day food records at baseline, during weeks one, 6, and 12, and was analyzed for energy and macro/micronutrient content using NUTRITIONIST PRO™ (Version 1.5, First Databank Inc, The Hearst Corporation, San Bruno, CA, USA). The nutrient analysis program had no missing values for the nutrients reported and the database was extensively updated with new foods and individualized recipes. All subjects were given a multi-vitamin/mineral complex that provided micronutrients at levels $\leq 100\%$ of the RDA.

The main goal of the VLCKD was to restrict carbohydrate to a level that induced a low level of ketosis. Subjects monitored their level of ketosis daily using urine reagent strips. In this diet there were no restrictions on the intake of fat from saturated and unsaturated sources or the intake of cholesterol. Examples of foods consumed by the subjects included unlimited amounts of beef, poultry, fish, eggs, oils and heavy cream; moderate amounts of hard cheeses, low carbohydrate vegetables and salad dressings; and small amounts of nuts, nut butters and seeds. Subjects restricted fruit and fruit juices, dairy products (with the exception of heavy cream and hard cheese), breads, grains, pasta, cereal, high carbohydrate vegetables, and desserts. Subjects were instructed to avoid all low carbohydrate breads and cereal products, and were limited to a maximum of one sugar alcohol-containing, low carbohydrate snack per day.

The LFD was designed to provide $<10\%$ of total calories from saturated fat and <300 mg cholesterol. Foods encouraged included whole grains (breads, cereals, and pastas), fruit/fruit juices, vegetables, vegetable oils, low-fat dairy and lean meat products. Standard diabetic exchange lists were used to ensure a macronutrient balance of protein ($\sim 20\%$ energy), fat ($\sim 25\%$ energy), and carbohydrate ($\sim 55\%$ of energy).

Blood Analyses

Whole blood was collected into tubes with no preservative or EDTA and centrifuged at $1500 \times g$ for 15 min and 4°C , and promptly aliquoted into separate storage tubes which were stored at 75°C until analyzed for serum fatty acid composition and plasma inflammatory markers. An aliquot

of anti-coagulated whole blood (~ 3 ml) was sent to a certified medical laboratory (Quest Diagnostics, Wallingford, CT, USA) for a white blood cell differential count.

Inflammatory Biomarkers

The Evidence Investigator™ Biochip Array technology (Randox Laboratories Ltd, UK) that uses sandwich chemiluminescent immunoassays to simultaneously detect multiple analytes from a single sample was used to determine the following serum cytokines and adhesion molecules: IL-6, IL-8, vascular endothelial growth factor (VEGF), TNF- α , IFN- γ , epidermal growth factor (EGF), monocyte chemoattractant protein-1 (MCP-1), intracellular cellular adhesion molecule-1 (ICAM-1), vascular cellular adhesion molecule-1 (VCAM-1), E-selectin, P-selectin and L-selectin. In addition, serum C-reactive protein (CRP) was determined on an IMMULITE Automated Analyzer using the commercially available immulite chemiluminescent enzyme immuno-metric assay (Immulite®, Diagnostic Products Corp, Los Angeles, CA, USA) and plasma plasminogen-activator inhibitor-1 (PAI-1) was determined utilizing the Luminex 200 analyzer (Luminex Corp, Austin, TX, USA) using an immunoassay kit from LINCO Research.

Fatty Acid Composition

Serum lipids were extracted according to the method of Bligh–Dyer whereby mixtures of plasma, methanol, chloroform and water were prepared such that lipid is recovered in a chloroform layer. The resulting lipid extracts were maintained under an atmosphere of nitrogen following extraction and kept frozen prior to additional processing. Immediately prior to lipid class separation, lipid samples were dried under a gentle stream of nitrogen, rediluted in $50 \mu\text{l}$ of chloroform and prepared for lipid class separation. Lipid classes including total TAG, PL and CE were separated on commercial silica gel G plates (AnalTech, Newark, DE, USA). The chromatographic plates were developed in a solvent system consisting of distilled petroleum ether (bp $30\text{--}60^\circ\text{C}$):diethyl ether:acetic acid (80:20:1, by vol). Following development, the silica gel plates were sprayed with a methanolic solution containing 0.5% 2,7-dichlorofluorescein which was then used to visualize lipid classes under ultraviolet light. Desired corresponding lipid bands were then scraped into Teflon line screw cap tubes. The samples were then transesterified with boron trifluoride (10%) in excess methanol (Supelco, Bellefonte, PA, USA) in an 80°C water bath for 90 min. Resulting fatty acid methyl esters were extracted with water and petroleum ether and stored frozen until gas chromatographic analysis was performed.

Lipid class fatty acid methyl ester composition was determined by capillary gas chromatography. Methyl ester samples were blown to dryness under nitrogen and resuspended in hexane. Resulting fatty acid methyl esters were separated and quantified with a Shimadzu capillary gas chromatograph (GC17) utilizing a 30 m Restek free fatty acid phase (FFAP) coating and EZChrom software. The instrument temperature was programmed from 190 to 240 °C at 7°C/min with a final hold of 10 min, separating and measuring fatty acid methyl esters ranging from 12:0 to 24:1. The detector temperature was 250 °C. Helium carrier gas was used at a flow rate of 1.4 ml/min. and a split ratio of 1:25. Chromatographic data was collected and processed with EZChrom software (Scientific Products, CA, USA). Fatty acids were identified by comparison to authentic fatty acid standards and quantitated with peak area and internal standard. Resulting data are expressed in percent composition. Individual peaks, representing as little as 0.05% of the fatty acid methyl esters, were distinguished.

Statistical Analyses

All statistical analyses were done with Statistica software (StatSoft Inc, Tulsa, OK, USA). A 2 × 2 ANOVA with

one between effect (VLCKD vs. LFD) and one within effect (Week 0 vs. Week 12) was used to compare biochemical responses over time in both groups. Significant main or interaction effects were further analyzed using a Fishers LSD post hoc test. Relationships among selected variables were examined using Pearson's product-moment correlation coefficient. The alpha level for significance was set at 0.05.

Results

Dietary Intake and MetS Responses

Dietary nutrient intake and responses of MetS biomarkers will be presented elsewhere [7]. In brief, subjects in both groups reduced energy intake to approximately 1500 kcal/day, but the diets had markedly different macronutrient distributions based upon the analysis of individual diet records (VLCKD, %CHO:fat:protein = 12:59:28) and (LFD, %CHO:fat:protein = 56:24:20) (Table 1). Dietary saturated fat and cholesterol intake were significantly higher during the VLCKD than the LFD. The LFD led to improvements in some metabolic markers, but subjects following the VLCKD had consistently greater weight loss,

Table 1 Daily nutrient intake and serum cholesterol responses of men and women who consumed low carbohydrate and low fat diets

Variables	VLCKD (<i>n</i> = 20)		LFD (<i>n</i> = 20)		2 × 2 ANOVA	
	Baseline	Intervention	Baseline	Intervention	Time	T × G
Energy (kcal)	2351 ± 617	1504 ± 494	2082 ± 445	1478 ± 435	0.000	0.154
Protein (g)	94.6 ± 28.5	104.8 ± 33.6	82.3 ± 17.6	71.5 ± 21.3	0.756	0.009
Protein (%)	16.2 ± 3.1	28.1 ± 4.4	15.8 ± 2.6	19.6 ± 4.4	0.000	0.000
Carbohydrate (g)	270.3 ± 67.2	44.8 ± 18.9	266.8 ± 74.7	208.3 ± 69.6	0.000	0.000
Carbohydrate (%)	46.6 ± 7.7	12.4 ± 5.2	50.9 ± 10.1	55.8 ± 7.9	0.000	0.000
Total Fat (g)	97.0 ± 35.2	100.2 ± 37.9	78.5 ± 29.5	40.0 ± 17.5	0.004	0.001
Total Fat (%)	36.2 ± 6.7	58.9 ± 5.4	33.0 ± 9.8	23.8 ± 6.8	0.000	0.000
Saturated Fat (g)	34.2 ± 14.3	36.4 ± 12.9	26.0 ± 11.1	11.7 ± 5.9	0.012	0.002
Monounsaturated Fat (g)	19.2 ± 6.5	26.4 ± 11.1	18.0 ± 9.6	8.9 ± 4.7	0.830	0.000
Polyunsaturated Fat (g)	12.4 ± 7.4	12.4 ± 7.8	10.6 ± 7.4	5.1 ± 3.1	0.064	0.019
18:1n-9 (g)	14.0 ± 5.0	20.9 ± 9.5	11.6 ± 6.9	6.5 ± 3.8	0.289	0.000
18:2n-6 (g)	7.4 ± 6.0	7.7 ± 5.1	5.8 ± 4.7	2.9 ± 2.0	0.215	0.042
18:3n-3 (mg)	989 ± 1199	879 ± 746	575 ± 398	325 ± 198	0.139	0.439
20:5n-3 (mg)	8 ± 10	46 ± 81	32 ± 50	32 ± 58	0.047	0.050
22:6n-3 (mg)	24 ± 24	117 ± 184	83 ± 116	82 ± 154	0.049	0.052
Alcohol (%)	0.9 ± 1.8	0.7 ± 1.4	0.3 ± 0.5	0.9 ± 2.0	0.232	0.056
Cholesterol (mg)	354 ± 120	605 ± 262	267 ± 111	144 ± 80	0.044	0.000
Dietary Fiber (g)	13.1 ± 3.5	9.4 ± 4.9	15.8 ± 6.6	17.3 ± 9.6	0.083	0.021
Serum total cholesterol (mg/dl)	208.0 ± 26.0	196.5 ± 34.9	204.0 ± 31.5	194.5 ± 34.0	0.016	0.816
Serum LDL-C (mg/dL)	130.4 ± 21.8	135.4 ± 31.4	127.9 ± 31.3	125.9 ± 32.1	0.357	0.357
Serum HDL-C (mg/dl)	35.8 ± 6.9	40.4 ± 9.6	38.7 ± 6.2	38.4 ± 5.5	0.001	0.000

Values are mean ± SD calculated from 7 days of weight food records at baseline (week 0) and 7 days during weeks 1, 6, and 12 (Intervention)

decreased adiposity, improved glycemic control and insulin sensitivity and more favorable TAG, HDL-C and total cholesterol/HDL-C ratio responses. In addition to these markers for MetS, the VLCKD subjects showed more favorable responses in alternative indicators of atherogenic dyslipidemia and cardiovascular risk: postprandial lipemia, apo B, apo A-1, the apo B/Apo A-1 ratio, LDL particle distribution and postabsorptive and postprandial vascular function. Most striking, we reported that despite a three-fold higher intake of dietary saturated fat during the VLCKD compared to the LFD, circulating saturated fatty acids in TAG and CE were significantly decreased, as was 16:1n-7, an endogenous marker of lipogenesis. There were profound changes, as well, in other fatty acids in circulating TG, PL, and CE fractions (Tables 2–4).

Circulating Triglyceride Fatty Acids

Compared to the LFD, consumption of the VLCKD resulted in a significantly greater increase in TG n-6 PUFA, mainly attributed to a marked increase in arachidonic acid: 17 of 20 subjects in VLCKD showed marked increases while only 7 of 20 subjects on LFD showed increases in 20:4n-6 and these were more modest in amplitude (Table 2). In both groups, n-3 PUFA was decreased due largely to lower α -linolenic acid (18:3n-3) and 20:5n-3. The n-6/n-3 and arachidonic/eicosapentaenoic acid ratios were, on average, nearly doubled in response to the VLCKD and virtually unchanged by the LFD: 15 of 20 subjects on VLCKD showed increases in the n-6/n-3 ratios, while only 8 of 20 of the LFD showed increases. In contrast to the response in 20:4n-6, the metabolic intermediates in the biosynthetic pathway, especially 20:3n-6, were decreased after the VLCKD. As previously reported, total MUFA was unchanged but 16:1n-7 and total SFA was significantly decreased in response to the VLCKD.

Circulating Phospholipid Fatty Acids

The pattern of fatty acid changes seen in the TAG fraction was also found in circulating phospholipids: consumption of the VLCKD was associated with an increase in n-6 PUFA, again primarily due to a distinct increase in 20:4n-6 (Fig 1a), whereas 18:3n-6 and 20:3n-6 were markedly decreased (Table 3). The VLCKD was associated with a significant reduction in 18:3n-3, 18:4n-3, 20:4n-3, and 20:5n-3. However docosahexaenoic acid (22:6n-3) was increased so that total n-3 PUFA was not significantly changed. Compared to the LFD, ingestion of the VLCKD resulted in a significant increase in total PUFA and the ratio of n-6/n-3 (Fig. 1b) and arachidonic/eicosapentaenoic acid

(Fig. 1c). In comparison to the LFD, total MUFA was significantly decreased in response to the VLCKD due to significant decreases in the most abundant MUFA, 18:1n-9, and a consistent reduction in 16:1n-7.

Circulating Cholesteryl Ester Fatty Acids

The patterns of CE fatty acid responses to diet resembled that in TG and PL, and in general were more dramatic in this lipid fraction (Table 4). Total n-6 PUFA was significantly increased in response to the VLCKD due to a large increase in 18:2n-6 and a smaller increase in 20:4n-6: most of the VLCKD group showed a significant increase in 20:4n-6 while only five of the LFD group showed an increase. On the other hand total n-3 PUFA was significantly decreased due to a reduced proportion of 18:3n-3 and 20:5n-3 in response to the VLCKD but, similar to other fractions, there was an increase in 22:6n-3. The n-6/n-3 and arachidonic/eicosapentaenoic acid ratios were unchanged in response to the LFD but increased sharply after consumption of the VLCKD. Total MUFA decreased in response to the VLCKD, again due to a reduced proportion of 18:1n-9 and a striking decrease in 16:1n-7.

Inflammatory Markers

Both diets led to a similar significant reduction in the acute phase reactant C-reactive protein (–23%), VEGF (–21%), P-selectin (–11%), and a trend for EGF (–38%), and V-CAM (–6%); however, there was an overall greater anti-inflammatory effect associated with the VLCKD as evidenced by significantly greater decreases in the proinflammatory cytokine TNF- α (–32 vs. –12%), the chemokines IL-8 (–33 vs. 4%) and MCP-1 (–24 vs. –5%), and the adhesion molecules E-selectin (–34 vs. –14%) and I-CAM (–17 vs. –3%) (Table 5). There was also a trend for a greater reduction in IL-6 (–35%) in response to the VLCKD ($P = 0.07$). Plasminogen-activator inhibitor-1 (PAI-1) has antifibrinolytic functions, and was also reduced more in subjects consuming the VLCKD compared to LFD (–34 vs. –8%). There was no effect of the interventions on leukocyte subpopulations.

Correlations

The results described above are surprising in that consumption of the VLCKD showed substantially greater increases in arachidonic acid and the arachidonic/eicosapentaenoic acid and n-6/n-3 ratios that are commonly viewed as contributing to an overall proinflammatory state,

Table 2 Serum triglyceride fatty acid responses of men and women who consumed low carbohydrate and low fat diets

Variables	VLCKD (<i>n</i> = 20)		Low Fat (<i>n</i> = 20)		2 × 2 ANOVA	
	Week 0	Week 12	Week 0	Week 12	Time	T × G
Total TG (mg/dl)	210.9 ± 57.9	103.7 ± 44.1	187.1 ± 57.6	151.2 ± 38.0	0.000	0.000
SFA						
12:0	0.09 ± 0.09	0.04 ± 0.06	0.06 ± 0.10	0.06 ± 0.13	0.271	0.108
14:0	1.94 ± 0.61	1.02 ± 0.40	1.86 ± 0.88	1.71 ± 0.61	0.000	0.001
15:0	0.27 ± 0.07	0.25 ± 0.05	0.28 ± 0.10	0.28 ± 0.08	0.478	0.527
16:0	27.07 ± 4.14	24.26 ± 1.65	24.86 ± 2.31	23.99 ± 1.86	0.002	0.092
18:0	3.66 ± 1.06	3.45 ± 0.66	3.32 ± 1.09	2.86 ± 0.48	0.051	0.466
20:0	0.06 ± 0.03	0.05 ± 0.04	0.04 ± 0.03	0.04 ± 0.03	0.354	0.901
22:0	0.03 ± 0.03	0.05 ± 0.03	0.03 ± 0.03	0.04 ± 0.03	0.079	0.584
24:0	0.01 ± 0.02	0.02 ± 0.04	0.00 ± 0.01	0.00 ± 0.00	0.514	0.155
Total SFA	33.13 ± 5.03	29.15 ± 1.39	30.45 ± 3.98	28.98 ± 2.45	0.000	0.086
MUFA						
14:1	0.22 ± 0.15	0.06 ± 0.09	0.18 ± 0.17	0.17 ± 0.13	0.000	0.004
15:1	0.04 ± 0.03	0.04 ± 0.05	0.03 ± 0.02	0.04 ± 0.04	0.627	0.659
16:1n-7	4.53 ± 1.07	3.10 ± 0.69	4.54 ± 0.98	4.53 ± 1.10	0.000	0.000
17:1	0.29 ± 0.06	0.26 ± 0.08	0.29 ± 0.10	0.29 ± 0.07	0.248	0.264
18:1n-9	36.31 ± 3.18	38.67 ± 2.73	38.91 ± 2.75	39.50 ± 2.90	0.015	0.132
20:1n-7	0.07 ± 0.03	0.05 ± 0.02	0.07 ± 0.02	0.07 ± 0.03	0.015	0.100
20:1n-9	0.27 ± 0.07	0.27 ± 0.08	0.31 ± 0.07	0.31 ± 0.07	0.912	0.672
22:1n-9	0.05 ± 0.03	0.05 ± 0.03	0.04 ± 0.03	0.03 ± 0.03	0.454	0.352
Total MUFA	41.78 ± 3.51	42.50 ± 2.99	44.37 ± 2.92	44.93 ± 3.25	0.292	0.900
n-6 PUFA						
18:2n-6	19.04 ± 3.58	22.19 ± 3.09	19.36 ± 4.36	19.99 ± 3.09	0.010	0.078
18:3n-6	0.45 ± 0.19	0.38 ± 0.17	0.38 ± 0.18	0.41 ± 0.23	0.517	0.102
20:2n-6	0.20 ± 0.07	0.18 ± 0.07	0.21 ± 0.08	0.21 ± 0.09	0.616	0.259
20:3n-6	0.34 ± 0.10	0.26 ± 0.06	0.33 ± 0.07	0.33 ± 0.08	0.001	0.003
20:4n-6	1.17 ± 0.35	1.70 ± 0.55	1.04 ± 0.27	1.16 ± 0.35	0.000	0.002
22:4n-6	0.18 ± 0.04	0.21 ± 0.06	0.17 ± 0.04	0.17 ± 0.04	0.040	0.049
22:5n-6	0.14 ± 0.07	0.27 ± 0.18	0.15 ± 0.10	0.13 ± 0.07	0.033	0.004
Total n-6	21.51 ± 3.59	25.18 ± 2.86	21.64 ± 4.24	22.39 ± 3.13	0.004	0.048
n-3 PUFA						
18:3n-3	1.10 ± 0.44	0.90 ± 0.51	1.04 ± 0.35	1.13 ± 0.60	0.494	0.080
18:4n-3	0.39 ± 0.21	0.27 ± 0.17	0.46 ± 0.20	0.44 ± 0.18	0.009	0.042
20:3n-3	0.04 ± 0.03	0.02 ± 0.02	0.03 ± 0.02	0.03 ± 0.04	0.054	0.051
20:4n-3	0.06 ± 0.04	0.02 ± 0.03	0.04 ± 0.03	0.04 ± 0.04	0.019	0.005
20:5n-3	0.15 ± 0.05	0.12 ± 0.04	0.13 ± 0.06	0.16 ± 0.11	0.696	0.025
22:5n-3	0.24 ± 0.06	0.29 ± 0.09	0.25 ± 0.08	0.28 ± 0.10	0.011	0.497
22:6n-3	0.31 ± 0.16	0.42 ± 0.16	0.27 ± 0.11	0.33 ± 0.23	0.019	0.486
Total n-3	2.30 ± 0.57	2.05 ± 0.63	2.22 ± 0.44	2.41 ± 0.72	0.790	0.039
n-9 PUFA						
20:3n-9	0.09 ± 0.04	0.12 ± 0.05	0.12 ± 0.06	0.13 ± 0.09	0.012	0.455
Total PUFA	23.90 ± 3.91	27.35 ± 3.11	23.97 ± 4.34	24.94 ± 3.56	0.006	0.106
Total HUFA	4.66 ± 0.73	4.98 ± 0.75	4.41 ± 0.64	4.74 ± 0.97	0.034	0.986
Total n-9	36.85 ± 3.24	39.05 ± 2.77	39.44 ± 2.68	40.02 ± 2.84	0.023	0.170
n-6/n-3	9.74 ± 2.20	13.16 ± 3.49	10.04 ± 2.47	9.74 ± 2.26	0.002	0.000
20:4n-6/20:5n-3	7.69 ± 1.82	14.76 ± 6.21	8.73 ± 3.44	9.33 ± 6.05	0.000	0.002

Values are weight percent (mean ± SD)




Fig. 1 Individual responses in serum phospholipid arachidonic acid (20:4n-6) (a), the n-6/n-3 ratio (b) and the arachidonic/eicosapentaenoic acid ratio (20:4n-6/20:5n-3) (c) in subjects who consumed a

very low carbohydrate ketogenic diet (VLCKD) or a low fat diet for 12 weeks. *Shaded bars* indicate mean responses

while simultaneously there was a significant decrease in many inflammatory markers. An analysis of these data bears out the idea that changes in the fatty acid proxies were consistently inversely associated with responses in most of the inflammatory markers we measured (Fig. 2). The fatty acid with the most consistent positive association with changes in inflammatory markers was palmitoleic acid (16:1n-7). The correlations between weight loss and changes in inflammatory markers were generally small and not significant. As shown in Fig. 3 for two of the more important markers TNF- α and IL-8, there is essentially no correlation.

Discussion

Because of the continued emphasis on dietary recommendations for cardiovascular disease and general health, the relation between dietary fat intake and plasma fatty acids and inflammatory markers is of great importance. The

findings presented here support our hypothesis that the components of metabolic syndrome are distinctly those that respond favorably to reduction in dietary carbohydrate [19]. Responses in fatty acid composition to the VLCKD in this study were exactly opposite to the fatty acid profile recently shown to be associated with development of metabolic syndrome over a 20 year period in previously healthy men (i.e., higher circulating 14:0, 16:0, 16:1n-7, 18:1n-9, 18:3n-6, and 20:3n-6, and lower levels of 18:2n-6) [1]. Abnormal fatty acid composition and inflammatory status are now recognized as prominent features of metabolic syndrome, and are reliably improved in subjects consuming a low carbohydrate diet compared to a low fat diet.

Acute ingestion of carbohydrate clearly induces an increase in reactive oxygen species and activation of pro-inflammatory pathways [9], and isocaloric high carbohydrate [20] and high glycemic [21] diets are associated with increased biomarkers of inflammation. In the context of hypocaloric diets, we showed that reducing dietary total

Table 3 Serum phospholipid fatty acid responses of men and women who consumed low carbohydrate and low fat diets

Variables	VLCKD (<i>n</i> = 20)		Low fat (<i>n</i> = 20)		2 × 2 ANOVA	
	Week 0	Week 12	Week 0	Week 12	Time	T × G
Total phospholipids (mg/dl)	196 ± 25	170 ± 33	183 ± 28	173 ± 30	0.001	0.135
SFA						
14:0	0.34 ± 0.12	0.28 ± 0.12	0.35 ± 0.13	0.36 ± 0.15	0.186	0.094
15:0	0.16 ± 0.03	0.17 ± 0.03	0.18 ± 0.06	0.18 ± 0.05	0.224	0.681
16:0	26.62 ± 1.64	26.87 ± 1.52	26.46 ± 1.59	27.02 ± 1.49	0.107	0.512
18:0	13.83 ± 1.25	12.76 ± 0.97	14.20 ± 1.58	13.56 ± 1.22	0.000	0.217
20:0	0.13 ± 0.04	0.18 ± 0.04	0.13 ± 0.03	0.13 ± 0.03	0.000	0.001
22:0	0.41 ± 0.11	0.57 ± 0.21	0.36 ± 0.11	0.35 ± 0.07	0.000	0.000
24:0	0.35 ± 0.11	0.48 ± 0.21	0.27 ± 0.12	0.26 ± 0.10	0.006	0.001
Total SFA	41.84 ± 1.30	41.31 ± 1.45	41.94 ± 1.17	41.88 ± 1.00	0.127	0.231
MUFA						
14:1	0.03 ± 0.06	0.07 ± 0.09	0.09 ± 0.09	0.10 ± 0.09	0.134	0.331
15:1	0.35 ± 0.11	0.54 ± 0.21	0.25 ± 0.16	0.29 ± 0.14	0.001	0.035
16:1n-7	0.92 ± 0.23	0.60 ± 0.17	0.86 ± 0.18	0.86 ± 0.23	0.000	0.000
17:1	0.28 ± 0.10	0.41 ± 0.17	0.26 ± 0.10	0.27 ± 0.08	0.002	0.007
18:1n-9	10.95 ± 1.60	9.88 ± 1.17	11.38 ± 0.94	11.67 ± 1.26	0.122	0.009
20:1n-7	0.05 ± 0.03	0.03 ± 0.01	0.04 ± 0.02	0.04 ± 0.02	0.011	0.020
20:1n-9	0.10 ± 0.02	0.12 ± 0.03	0.12 ± 0.05	0.13 ± 0.03	0.000	0.244
22:1n-9	0.05 ± 0.06	0.06 ± 0.04	0.06 ± 0.06	0.06 ± 0.05	0.754	0.654
24:1	0.42 ± 0.13	0.58 ± 0.22	0.37 ± 0.11	0.42 ± 0.11	0.000	0.041
Total MUFA	13.14 ± 1.68	12.29 ± 1.14	13.43 ± 1.09	13.84 ± 1.37	0.392	0.015
n-6 PUFA						
18:2n-6	22.99 ± 3.09	23.74 ± 2.69	22.66 ± 3.09	22.13 ± 2.74	0.807	0.162
18:3n-6	0.17 ± 0.06	0.10 ± 0.02	0.14 ± 0.04	0.14 ± 0.03	0.000	0.002
20:2n-6	0.29 ± 0.05	0.25 ± 0.07	0.34 ± 0.09	0.32 ± 0.08	0.008	0.234
20:3n-6	3.67 ± 0.82	2.29 ± 0.55	3.78 ± 0.76	3.50 ± 0.72	0.000	0.000
20:4n-6	11.54 ± 2.05	13.70 ± 1.82	11.31 ± 2.05	11.48 ± 1.97	0.000	0.001
22:4n-6	0.44 ± 0.08	0.40 ± 0.09	0.43 ± 0.10	0.42 ± 0.09	0.023	0.222
22:5n-6	0.41 ± 0.13	0.39 ± 0.11	0.38 ± 0.10	0.36 ± 0.13	0.379	0.883
Total n-6	39.50 ± 2.17	40.86 ± 2.04	39.04 ± 1.53	38.34 ± 1.53	0.246	0.001
n-3 PUFA						
18:3n-3	0.20 ± 0.08	0.15 ± 0.06	0.15 ± 0.07	0.19 ± 0.13	0.684	0.015
18:4n-3	0.13 ± 0.04	0.08 ± 0.04	0.13 ± 0.05	0.13 ± 0.07	0.000	0.003
20:3n-3	0.03 ± 0.02	0.03 ± 0.02	0.04 ± 0.03	0.04 ± 0.04	0.752	0.999
20:4n-3	0.12 ± 0.06	0.03 ± 0.02	0.10 ± 0.02	0.09 ± 0.05	0.000	0.000
20:5n-3	0.61 ± 0.20	0.42 ± 0.15	0.60 ± 0.27	0.68 ± 0.48	0.264	0.009
22:5n-3	0.81 ± 0.15	0.74 ± 0.16	0.87 ± 0.22	0.86 ± 0.20	0.044	0.104
22:6n-3	2.43 ± 0.84	2.80 ± 0.81	2.48 ± 0.62	2.71 ± 0.83	0.023	0.592
Total n-3	4.33 ± 0.90	4.24 ± 0.89	4.37 ± 0.80	4.69 ± 1.19	0.419	0.164
n-9 PUFA						
20:3n-9	0.09 ± 0.03	0.06 ± 0.03	0.10 ± 0.06	0.10 ± 0.05	0.048	0.092
Total PUFA	43.92 ± 1.89	45.17 ± 1.76	43.51 ± 1.11	43.14 ± 1.16	0.073	0.001
Total HUFA	20.64 ± 2.58	21.19 ± 1.90	20.51 ± 2.50	20.68 ± 2.32	0.323	0.599
Total n-9	11.55 ± 1.59	10.71 ± 1.16	12.02 ± 0.98	12.38 ± 1.29	0.341	0.021
n-6/n-3	9.55 ± 2.29	10.11 ± 2.46	9.24 ± 1.75	8.58 ± 1.84	0.879	0.062
20:4n-6/20:5n-3	21.59 ± 11.05	37.41 ± 16.28	21.86 ± 8.52	20.52 ± 8.20	0.000	0.000

Values are weight percent (mean ± SD)

Table 4 Serum cholesteryl ester fatty acid responses of men and women who consumed low carbohydrate and low fat diets

Variables	VLCKD (<i>n</i> = 20)		Low fat (<i>n</i> = 20)		2 × 2 ANOVA	
	Week 0	Week 12	Week 0	Week 12	Time	T × G
Total cholesteryl ester (mg/dl)	224 ± 35	224 ± 47	215 ± 42	199 ± 31	0.337	0.308
SFA						
14:0	0.79 ± 0.18	0.51 ± 0.13	0.69 ± 0.23	0.59 ± 0.24	0.000	0.010
15:0	0.17 ± 0.07	0.15 ± 0.05	0.14 ± 0.07	0.13 ± 0.09	0.274	0.475
16:0	11.23 ± 1.13	10.40 ± 0.84	10.79 ± 1.03	10.67 ± 0.88	0.011	0.052
18:0	1.15 ± 0.28	1.00 ± 0.22	1.29 ± 0.64	1.24 ± 0.69	0.268	0.596
20:0	0.05 ± 0.05	0.06 ± 0.03	0.05 ± 0.04	0.09 ± 0.09	0.009	0.035
22:0	0.01 ± 0.03	0.01 ± 0.01	0.01 ± 0.01	0.00 ± 0.01	0.222	0.501
24:0	0.01 ± 0.01	0.00 ± 0.01	0.02 ± 0.09	0.01 ± 0.05	0.737	0.863
Total SFA	13.41 ± 1.48	12.13 ± 0.91	12.98 ± 1.29	12.74 ± 1.21	0.002	0.028
MUFA						
14:1	0.79 ± 0.59	0.71 ± 0.56	0.94 ± 0.66	0.94 ± 0.63	0.785	0.779
15:1	0.05 ± 0.03	0.04 ± 0.05	0.02 ± 0.02	0.04 ± 0.09	0.606	0.218
16:1n-7	3.28 ± 0.90	1.84 ± 0.46	3.02 ± 1.01	2.98 ± 1.20	0.000	0.000
17:1	0.17 ± 0.09	0.14 ± 0.08	0.18 ± 0.08	0.16 ± 0.08	0.154	0.829
18:1n-9	17.77 ± 2.89	16.47 ± 1.69	17.52 ± 1.77	17.97 ± 1.44	0.290	0.034
20:1n-9	0.06 ± 0.06	0.04 ± 0.03	0.10 ± 0.10	0.11 ± 0.12	0.653	0.499
22:1n-9	0.02 ± 0.05	0.01 ± 0.03	0.04 ± 0.16	0.01 ± 0.03	0.260	0.583
24:1	0.00 ± 0.00	0.00 ± 0.02	0.03 ± 0.12	0.00 ± 0.00	0.444	0.263
Total MUFA	21.95 ± 2.47	22.22 ± 1.71	22.14 ± 3.65	19.26 ± 2.06	0.015	0.004
n-6 PUFA						
18:2n-6	52.41 ± 4.90	56.44 ± 4.08	53.23 ± 4.52	53.05 ± 3.60	0.014	0.008
18:3n-6	1.05 ± 0.40	0.50 ± 0.16	0.95 ± 0.33	0.92 ± 0.28	0.000	0.000
20:2n-6	0.07 ± 0.10	0.04 ± 0.03	0.05 ± 0.06	0.04 ± 0.05	0.093	0.483
20:3n-6	0.90 ± 0.23	0.59 ± 0.13	0.89 ± 0.17	0.85 ± 0.17	0.000	0.000
20:4n-6	7.39 ± 1.73	7.78 ± 1.73	7.57 ± 1.73	7.74 ± 1.75	0.001	0.008
22:4n-6	0.00 ± 0.00	0.00 ± 0.01	0.00 ± 0.01	0.00 ± 0.00	0.672	0.173
22:5n-6	0.05 ± 0.03	0.04 ± 0.04	0.09 ± 0.18	0.08 ± 0.16	0.855	0.997
Total n-6	61.87 ± 5.22	66.57 ± 2.89	62.79 ± 3.23	62.69 ± 2.47	0.003	0.002
n-3 PUFA						
18:3n-3	0.60 ± 0.15	0.45 ± 0.14	0.51 ± 0.11	0.53 ± 0.21	0.056	0.009
18:4n-3	0.14 ± 0.05	0.08 ± 0.04	0.14 ± 0.04	0.10 ± 0.09	0.001	0.363
20:3n-3	0.03 ± 0.03	0.03 ± 0.05	0.04 ± 0.07	0.02 ± 0.03	0.169	0.320
20:4n-3	0.05 ± 0.07	0.01 ± 0.03	0.03 ± 0.04	0.02 ± 0.03	0.002	0.128
20:5n-3	0.50 ± 0.16	0.37 ± 0.10	0.57 ± 0.26	0.61 ± 0.37	0.154	0.017
22:5n-3	0.03 ± 0.08	0.01 ± 0.01	0.02 ± 0.02	0.03 ± 0.06	0.759	0.165
22:6n-3	0.40 ± 0.12	0.45 ± 0.14	0.37 ± 0.12	0.44 ± 0.18	0.012	0.520
Total n-3	1.74 ± 0.27	1.39 ± 0.23	1.67 ± 0.33	1.75 ± 0.52	0.015	0.000
Total PUFA	63.61 ± 5.15	67.96 ± 2.85	64.46 ± 3.15	64.44 ± 2.37	0.004	0.004
Total HUFA	1.13 ± 1.58	11.48 ± 1.88	11.17 ± 1.98	11.35 ± 1.84	0.308	0.743
Total n-9	18.64 ± 3.18	17.25 ± 1.78	18.63 ± 1.83	19.02 ± 1.37	0.280	0.057
n-6/n-3	36.69 ± 8.46	49.59 ± 10.34	39.24 ± 9.32	38.26 ± 9.35	0.000	0.000
20:4n-6/20:5n-3	16.24 ± 6.80	26.56 ± 11.83	15.63 ± 7.87	14.59 ± 4.94	0.001	0.000

Values are weight percent (mean ± SD)

Table 5 Inflammatory responses of men and women who consumed low carbohydrate and low fat diets

Variables	VLCKD (<i>n</i> = 20)		Low fat (<i>n</i> = 20)		2 × 2 ANOVA	
	Week 0	Week 12	Week 0	Week 12	Time	T × G
WBC ($\times 10^9/l$)	6.2 ± 1.4	5.9 ± 1.4	5.9 ± 1.8	5.9 ± 2.2	0.471	0.427
Neutrophils ($\times 10^9/\mu l$)	3507 ± 877	3460 ± 1172	3368 ± 1500	3428 ± 1460	0.971	0.783
Lymphocytes ($\times 10^9/\mu l$)	2039 ± 648	1741 ± 439	1899 ± 509	1892 ± 668	0.076	0.090
Monocytes ($\times 10^9/\mu l$)	402 ± 135	451 ± 215	506 ± 274	422 ± 153	0.659	0.106
Eosinophils ($\times 10^9/\mu l$)	210 ± 169	176 ± 130	184 ± 105	164 ± 81	0.297	0.785
Basophils ($\times 10^9/\mu l$)	26 ± 21	21 ± 17	24 ± 13	27 ± 17	0.752	0.310
CRP (mg/dl)	0.6 ± 0.6	0.5 ± 0.5	0.4 ± 0.5	0.3 ± 0.4	0.028	0.858
IL-6 (pg/ml)	8.4 ± 9.3	5.5 ± 7.6	6.3 ± 8.7	6.3 ± 9.0	0.064	0.073
IL-8 (pg/ml)	8.5 ± 4.4	5.7 ± 2.8	9.4 ± 9.7	9.8 ± 11.0	0.033	0.007
VEGF (pg/ml)	162 ± 130	122 ± 96	129 ± 130	109 ± 113	0.004	0.293
TNF- α (pg/ml)	2.8 ± 1.6	1.9 ± 2.0	2.6 ± 1.8	2.3 ± 1.7	0.000	0.017
IFN- γ (pg/ml)	2.2 ± 1.5	1.7 ± 1.9	2.0 ± 1.4	2.2 ± 1.5	0.543	0.261
EGF (pg/ml)	12.6 ± 11.6	6.9 ± 8.1	20.7 ± 22.4	13.7 ± 22.9	0.060	0.841
MCP-1 (pg/ml)	380 ± 134	288 ± 120	323 ± 102	307 ± 123	0.002	0.023
I-CAM (ng/ml)	360 ± 84	299 ± 64	338 ± 69	328 ± 57	0.001	0.008
V-CAM (ng/ml)	549 ± 101	512 ± 113	567 ± 139	536 ± 135	0.060	0.874
E-selectin (ng/ml)	18.9 ± 9.2	12.4 ± 5.0	16.7 ± 5.3	14.4 ± 4.1	0.000	0.014
P-selectin (ng/ml)	125 ± 27	107 ± 27	122 ± 28	112 ± 28	0.002	0.301
L-selectin (ng/ml)	1148 ± 210	1091 ± 197	1081 ± 167	1098 ± 126	0.398	0.128
PAI-1 (ng/ml)	45.0 ± 20.7	29.5 ± 10.1	38.3 ± 11.5	35.2 ± 12.6	0.001	0.026

Values are mean ± SD





Fig. 2 Associations between changes in markers of inflammation and changes in PL arachidonic acid (a), and the 20:4n-6/20:5n-3 ratio (b). Individual bars represent Pearson correlation coefficients ($P < 0.05$)

and saturated fat only had a small effect on circulating inflammatory markers whereas reducing carbohydrate led to considerably greater reductions in a number of proinflammatory cytokines, chemokines, and adhesion molecules. These data implicate dietary carbohydrate rather than dietary fat as a more significant nutritional factor contributing to inflammatory processes; although increased fat in the presence of high carbohydrate may be

particularly deleterious. Dietary carbohydrate also has a fundamental role in determining fatty acid composition of lipids and membranes, and it is the endogenous fatty acids (as opposed to the exogenous dietary fatty acids) that influence inflammation by acting as ligands for receptors or transcription factors that regulate inflammatory signaling cascades or serving as substrates for proinflammatory bioactive products.

Fig. 3 Associations between weight loss and changes in TNF- α and IL-8



Despite the two diet groups consuming roughly the same caloric intake and all losing at least some weight, there were larger reductions in the VLCKD group in TNF- α , IL-8, MCP-1, PAI-1, E-selectin and I-CAM, while these markers showed little change on low fat suggesting that it is the macronutrient composition not weight loss or caloric reduction that is key. Most of the inflammatory markers did not correlate with weight loss. A correlation would not have proved that weight loss caused change in inflammatory markers but the lack of correlation makes it extremely unlikely. As shown in Fig. 3, there is essentially no correlation and if anything the associations tend to go in the opposite direction of what is expected if weight loss caused change in markers. In both cases, individuals with the largest reductions in inflammatory markers tended to be in the middle of the weight-loss range. The question of weight loss as a stimulus versus a response has been raised before with regard to other effects of carbohydrate restriction. Our group [22] and others [16, 18, 23] have consistently shown that there is a benefit to atherogenic dyslipidemia, glycemic control, and insulin from reduction in carbohydrate independent of weight loss. We therefore suggest that reduction in carbohydrate is primary, and weight loss (more precisely caloric restriction) is not the controlling variable.

One of the most striking responses in fatty acid composition was the increase in arachidonic acid and total n-6 PUFA in subjects consuming a VLCKD. Rather than being a negative factor within lipid membranes, increased arachidonic acid appears to be a beneficial outcome of weight-reducing diets associated with greater lipolysis [24]. The increase in plasma arachidonic acid only in response to the low carbohydrate diet is best explained by decreased degradation presumably due to less interaction with reactive oxygen species [25]. Increased production from 18:2n-6 was unlikely since the metabolic intermediates 18:3n-6 and 20:3n-6 were reduced in all three circulating fractions and there was no increase in 20:3n-9, which typically occurs in cases where PUFA anabolism is increased [13, 25]. Since

arachidonic acid was elevated in all circulating fractions, a shift from other pools is unlikely. This is supported by the fact that fat loss was only moderately greater on the VLCKD compared to the LFD (−5.6 vs. −3.7 kg), and by week 12, the rate of weight loss on both diets was low. Given that daily dietary contribution of arachidonic acid is on the order of 0.5% of the total body pool [26] also suggests reduced degradation as the major explanation. Thus, an increase in the proportion of arachidonic acid resulting from a diet that restricts carbohydrate may be due to lower catabolism (i.e. better preservation) and therefore reduced formation of proinflammatory products. The consistent inverse associations between changes in arachidonic acid and responses in inflammatory markers indicate that the adverse effects of arachidonic acid are due to metabolites produced subsequent to its release from membranes rather than the proportion of the intact fatty acid.

The 19% rise in PL arachidonic acid in the low carbohydrate group (from 11.54 to 13.70 wt%) is consistent with the change seen after 12 weeks of a very low calorie diet in a more obese population (e.g., from 9.16 to 11.77 wt%) [24]. Given the regulatory role of arachidonic acid as a ligand for PPAR and in gene expression (e.g., fatty acid synthase) [27], this degree of rise in 20:4n-6 has the potential to influence fuel partitioning. In the obese Zucker rat, the increase in liver PL arachidonic acid from 22.68 to 25.23 wt% (an 11% change) induced by feeding 18:3n-6 was associated with significant reductions in food intake and body fat content [28].

Scenarios associated with less oxidative stress should result in better preservation of the substrate arachidonic acid, due to the interaction of free radicals with several steps in its metabolism. Inflammatory cytokines are known to increase production of hydroxyl radicals which in turn initiate arachidonic acid release and breakdown. The VLCKD in this study resulted in significantly greater reductions in several proinflammatory markers including TNF- α , E-selectin, ICAM-1, and IL-8, that were related to

the increase in arachidonic acid. The significantly greater reduction in TNF- α in subjects following the VLCKD is of interest in that it is one of the agents known to activate NF- κ B a major transcription factor regulating cytokines, chemokines and adhesion molecules (TNF- α , MCP-1, IL-8, E-selectin, and ICAM-1) [12, 29]. The reduction in all of these agents by the VLCKD suggests that the antiinflammatory effects of carbohydrate restriction may be mediated via down regulation of NF- κ B expression [30]. We have previously found that guinea pigs fed high-cholesterol atherogenic diets demonstrated significant increases in aortic TNF- α , an effect that was attenuated by reduction in dietary carbohydrate [31].

Hypercaloric high carbohydrate feeding stimulates the production of several fatty acids including 16:0, the major lipogenic product, and palmitoleic acid (16:1n-7), the product of Δ 9 desaturase. Palmitoleic acid is a minor constituent in dietary fat and its increase is a marker of lipogenesis [32] and its presence has been linked to higher levels of adiposity [33, 34]. In this study, the VLCKD resulted in concurrent reductions in both 16:0 and 16:1n-7 in both TG and CE lipid fractions despite an increase in dietary saturated fat load. The significant reduction in dietary saturated fat in the LFD led to little decrease in total saturates and essentially no change in 16:1n-7, with one subject actually showing a drastic increase. The greater decrease in circulating SFA in response to carbohydrate restriction may have contributed to the larger decline in several inflammatory markers that are regulated by NF- κ B [10, 11]. The decrease in circulating saturated fatty acids on the VLCKD is likely due to greater oxidation of the saturated fat from both diet and endogenous lipolysis, and a reduction in de novo lipogenesis.

In summary, carbohydrate restricted diets that are proportionately high in saturated fatty acids show very different results from what might be expected [7, 18]. A VLCKD significantly increases arachidonic acid levels, presumably due to a better preservation as a result of reduced oxidative stress and decreased inflammation. Sparing of arachidonic acid (by reducing its degradation to oxy-lipids) may provide a signaling mechanism by which dietary carbohydrate restriction favorably alters lipid metabolism and inflammatory processes [27].

Acknowledgments This work was supported by the Dr. Robert C. Atkins Foundation.

References

1. Warensjo E, Riserus U, Vessby B (2005) Fatty acid composition of serum lipids predicts the development of the metabolic syndrome in men. *Diabetologia* 48:1999–2005
2. Dougherty RM, Galli C, Ferro-Luzzi A, Iacono JM (1987) Lipid and phospholipid fatty acid composition of plasma, red blood cells, and platelets and how they are affected by dietary lipids: a study of normal subjects from Italy, Finland, and the USA. *Am J Clin Nutr* 45:443–455
3. King IB, Lemaitre RN, Kestin M (2006) Effect of a low-fat diet on fatty acid composition in red cells, plasma phospholipids, and cholesterol esters: investigation of a biomarker of total fat intake. *Am J Clin Nutr* 83:227–236
4. Raatz SK, Bibus D, Thomas W, Kris-Etherton P (2001) Total fat intake modifies plasma fatty acid composition in humans. *J Nutr* 131:231–234
5. Phinney SD (2006) The low fat paradox—do dietary carbohydrates increase circulating saturated fatty acids? *Am J Clin Nutr* 84:461–462
6. Parks EJ (2002) Changes in fat synthesis influenced by dietary macronutrient content. *Proc Nutr Soc* 61:281–286
7. Volek JS, Feinman RD, Phinney SD, Forsythe CE, Silvestre R, Judelson D, Quann EE, Wood RJ, Puglisi MJ, LaBonte CC, Kraemer WJ, Bibus DM, Contois JH, Fernandez ML (2007) Comparative effects of dietary restriction of carbohydrate or fat on circulating saturated fatty acids and atherogenic dyslipidemia. (Submitted)
8. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. *Diabetes* 37:1595–1607
9. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R (2005) Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. *Circulation* 111:1448–1454
10. Lee JY, Hwang DH (2006) The modulation of inflammatory gene expression by lipids: mediation through Toll-like receptors. *Mol Cells* 21:174–185
11. Lee JY, Zhao L, Youn HS, Weatherill AR, Tapping R, Feng L, Lee WH, Fitzgerald KA, Hwang DH (2004) Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. *J Biol Chem* 279:16971–16979
12. de Winther MP, Kanters E, Kraal G, Hofker MH (2005) Nuclear factor kappaB signaling in atherogenesis. *Arterioscler Thromb Vasc Biol* 25:904–914
13. Calder PC (2006) Polyunsaturated fatty acids and inflammation. *Prostaglandins Leukot Essent Fatty Acids* 75(3):197–202
14. Johnston CS, Tjonn SL, Swan PD, White A, Hutchins H, Sears B (2006) Ketogenic low-carbohydrate diets have no metabolic advantage over nonketogenic low-carbohydrate diets. *Am J Clin Nutr* 83:1055–1061
15. Peplow PV (1996) Actions of cytokines in relation to arachidonic acid metabolism and eicosanoid production. *Prostaglandins Leukot Essent Fatty Acids* 54:303–317
16. Feinman RD, Volek JS (2006) Low carbohydrate diets improve atherogenic dyslipidemia even in the absence of weight loss. *Nutr Metab (Lond)* 3:24
17. Feinman RD, Westman EC, Volek JS (2006) Low carbohydrate and low fat diets in diabetes, cardiovascular disease and metabolic syndrome. *Cellscience Reviews* 3, no. 1 (http://www.cellscience.com/reviews9/Low_carbohydrate_low_fat_diets_in_disease.html)
18. Krauss RM, Blanche PJ, Rawlings RS, Fernstrom HS, Williams PT (2006) Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia. *Am J Clin Nutr* 83:1025–1031
19. Volek JS, Feinman RD (2005) Carbohydrate restriction improves the features of metabolic syndrome. Metabolic syndrome may be defined by the response to carbohydrate restriction. *Nutr Metab (Lond)* 2:31
20. Kasim-Karakas SE, Tsodikov A, Singh U, Jialal I (2006) Responses of inflammatory markers to a low-fat, high-carbohydrate diet: effects of energy intake. *Am J Clin Nutr* 83:774–779

21. Liu S, Manson JE, Buring JE, Stampfer MJ, Willett WC, Ridker PM (2002) Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. *Am J Clin Nutr* 75:492–498
22. Volek JS, Sharman MJ, Gomez AL, Scheett TP, Kraemer WJ (2003) An isoenergetic very low carbohydrate diet improves serum HDL cholesterol and triacylglycerol concentrations, the total cholesterol to HDL cholesterol ratio and postprandial lipemic responses compared with a low fat diet in normal weight, normolipidemic women. *J Nutr* 133:2756–2761
23. Gannon MC, Nuttall FQ (2006) Control of blood glucose in type 2 diabetes without weight loss by modification of diet composition. *Nutr Metab (Lond)* 3:16
24. Phinney SD, Davis PG, Johnson SB, Holman RT (1991) Obesity and weight loss alter serum polyunsaturated lipids in humans. *Am J Clin Nutr* 53:831–838
25. Sullivan PG, Rippy NA, Dorenbos K, Concepcion RC, Agarwal AK, Rho JM (2004) The ketogenic diet increases mitochondrial uncoupling protein levels and activity. *Ann Neurol* 55:576–580
26. Zhou L, Nilsson A (2001) Sources of eicosanoid precursor fatty acid pools in tissues. *J Lipid Res* 42:1521–1542
27. Brash AR (2001) Arachidonic acid as a bioactive molecule. *J Clin Invest* 107:1339–1345
28. Phinney SD, Tang AB, Thurmond DC, Nakamura MT, Stern JS (1993) Abnormal polyunsaturated lipid metabolism in the obese Zucker rat, with partial metabolic correction by gamma-linolenic acid administration. *Metabolism* 42:1127–1140
29. Monaco C, Paleolog E (2004) Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. *Cardiovasc Res* 61:671–682
30. Shin WS, Szuba A, Rockson SG (2002) The role of chemokines in human cardiovascular pathology: enhanced biological insights. *Atherosclerosis* 160:91–102
31. Fernandez ML, Volek JS (2006) Guinea pigs: a suitable animal model to study lipoprotein metabolism, atherosclerosis and inflammation. *Nutr Metab (Lond)* 3:17
32. Aarsland A, Wolfe RR (1998) Hepatic secretion of VLDL fatty acids during stimulated lipogenesis in men. *J Lipid Res* 39:1280–1286
33. Okada T, Furuhashi N, Kuromori Y, Miyashita M, Iwata F, Harada K (2005) Plasma palmitoleic acid content and obesity in children. *Am J Clin Nutr* 82:747–750
34. Kunesova M, Hainer V, Tvrzicka E, Phinney SD, Stich V, Parizkova J, Zak A, Stunkard AJ (2002) Assessment of dietary and genetic factors influencing serum and adipose fatty acid composition in obese female identical twins. *Lipids* 37:27–32